TiGenix reconfirms its strategic focus on its allogeneic stem cell platforms – GlobeNewswire (press release)
|
TiGenix reconfirms its strategic focus on its allogeneic stem cell platforms
GlobeNewswire (press release) This decision is in line with TiGenix's strategy to concentrate its resources and capabilities on its allogeneic stem cell platforms, its upcoming Cx601 Phase III US trial and its other clinical stage assets. Due to the regulatory environment around … |
